1-((6-bromopyridin-3-yl)methyl)-4-methylpiperazine | 364794-55-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-((6-bromopyridin-3-yl)methyl)-4-methylpiperazine
• 英文别名: 1-[(6-bromopyridin-3-yl)methyl]-4-methylpiperazine
• CAS: 364794-55-8
• 化学式: C₁₁H₁₆BrN₃
• 分子量: 270.172
• InChiKey: MUKOKIXKKLJMMH-UHFFFAOYSA-N

物化性质

• 沸点：
  351.3±37.0 °C(Predicted)
• 密度：
  1.376±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  19.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-((6-bromopyridin-3-yl)methyl)-4-methylpiperazine 在 [1,1'-biphenyl]-2-yldicyclohexylphosphine oxide 、 tris-(dibenzylideneacetone)dipalladium(0) 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 12.0h， 生成 2-氨基-5-[(4-甲基-1-哌嗪基)甲基]吡啶
  参考文献：
  名称：

  Design and synthesis of 4-(2,3-dihydro-1 H -benzo[ d ]pyrrolo[1,2- a ]imidazol-7-yl)- N -(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships

  摘要：

  Cyclin-dependent kinases 4/6 play an important role in regulation of cell cycle, and overexpress in a variety of cancers. Up to now, new CDK inhibitors still need to be developed due to its poor selectivity. Herein we report a novel series of 4-(2,3-dihydro-1H-benzo[d] pyrrolo[1,2-a] imidazole-7-yl)-N-(5-(piperazin-1-ylmethyl) pyridine-2-yl) pyrimidin-2-amine anologues as potent CDK 4/6 inhibitors based on LY2835219 (Abemaciclib). Compound 10d, which exhibits approximate potency on CDK4/6 (IC50 = 7.4/0.9 nM), has both good pharmacokinetic characters and high selectivity on CDK1 compared with LY2835219. Overall, compound 10d could be a promising candidate and a good starting point as anticancer drugs. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.12.068
• 作为产物：
  描述：

  4-Bromo-1-methylpiperazine 、 2-溴-5-醛基吡啶 在 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以85%的产率得到1-((6-bromopyridin-3-yl)methyl)-4-methylpiperazine
  参考文献：
  名称：

  一种蛋白激酶抑制剂及其制备方法和医药用途

  摘要：

  本发明提供一种结构式I的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式，或结构式I的化合物、其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体的药学上可以接受的盐或溶剂化物，A环、R1、R2、R3和R4如说明书中的定义。本发明还提供所述结构式I的化合物的制备方法及其在制备用于治疗细胞增殖障碍性疾病的药物中的应用。

  公开号：

  CN106608879A

文献信息

• [EN] SUBSTITUTED (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-a] PYRIMIDINE AND IMIDAZO [1, 2-b] PYRIDAZINE COMPOUNDS AS TRK KINASES INHIBITORS<br/>[FR] COMPOSÉS DE (2-AZABICYCLO [3.1.0] HEXAN-2-YL) PYRAZOLO [1, 5-A] PYRIMIDINE ET IMIDAZO [1, 2-B] PYRIDAZINE SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE KINASES TRK
  申请人：FOCHON PHARMACEUTICALS LTD

  公开号：WO2021047584A1

  公开（公告）日：2021-03-18

  Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

  提供了某些TRK抑制剂，其药物组合物以及使用方法。
• [EN] CDK4/6 INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE CDK4/6 ET LEUR UTILISATION
  申请人：BEIJING XUANYI PHARMASCIENCES CO LTD

  公开号：WO2019035008A1

  公开（公告）日：2019-02-21

  The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, a stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (A) or formula (B), and any subgenera thereof, and use of said compounds and compositions thereof, wherein R1, R2, R3a, R3b, R5, R6, X1, X2, Y and n are described herein.

  本公开涉及式(I)的化合物，或其药用可接受的盐、溶剂合物、立体异构体或互变异构体，包括化合物(A)或化合物(B)的药物组合物，以及所述化合物和组合物的使用，其中R1、R2、R3a、R3b、R5、R6、X1、X2、Y和n如本文所述。
• 7-(Aryl/heteroaryl-2-ylethynyl)-4-phenylamino-3-quinolinecarbonitriles as new Src kinase inhibitors: Addition of water solubilizing groups
  作者：Biqi Wu、Ana Carolina Barrios Sosa、Diane H. Boschelli、Frank Boschelli、Erick E. Honores、Jennifer M. Golas、Dennis W. Powell、Yanong D. Wang

  DOI：10.1016/j.bmcl.2006.05.015

  日期：2006.8

  necarbonitriles with a 7-ethynyl group substituted by a pyridine, phenyl or thiophene ring containing basic water solubilizing groups were prepared and evaluated as Src kinase inhibitors. Of these new analogs, potent activity was observed with compounds having a (2,4-dichloro-5-methoxyphenyl)amino group at C-4, a methoxy or ethoxy group at C-6, and a pyridyl group bearing a dimethylamine or N-methylpiperazine

  制备具有被含碱性水增溶基团的吡啶，苯基或噻吩环取代的7-乙炔基的新的4-苯基氨基-3-喹啉甲腈，并将其评价为Src激酶抑制剂。在这些新的类似物中，观察到具有在C-4具有（2,4-二氯-5-甲氧基苯基）氨基，在C-6具有甲氧基或乙氧基以及带有二甲胺或N的吡啶基的化合物的有效活性。 -甲基哌嗪在C-7的乙炔基上。
• [EN] 2H-INDAZOLE DERIVATIVES AS CDK4 AND CDK6 INHIBITORS AND THERAPEUTIC USES THEREOF<br/>[FR] DÉRIVÉS DE 2-H-INDAZOLE EN TANT QU'INHIBITEURS DE CDK4 ET CDK6 ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：BETA PHARMA INC

  公开号：WO2019148161A1

  公开（公告）日：2019-08-01

  2-Aminopyrimidine-substituted 2H-indazole compounds of formula (I), where R1 is hydrogen, and their prodrugs, where R1 is a metabolizable group under physiological conditions, as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.

  公开了具有式（I）的2-Aminopyrimidine取代的2H-吲唑化合物，其中R1为氢，以及它们的前药，其中R1在生理条件下是可代谢的基团，作为细胞周期蛋白依赖性激酶（CDK）和细胞增殖抑制剂，并公开了其治疗用途和制备方法。这些化合物及其药学上可接受的盐、溶剂合物、前药和药物组合物可用于治疗与细胞周期蛋白依赖性激酶活性相关的疾病和疾病，特别是CDK4/6，包括但不限于各种癌症和炎症相关的疾病或症状。
• MERTK-SPECIFIC PYRIMIDINE COMPOUNDS
  申请人：The University of North Carolina at Chapel Hill

  公开号：US20150291609A1

  公开（公告）日：2015-10-15

  The present invention includes pyrimidine compounds that selectively inhibit Mer tyrosine kinase (MerTK) activity and/or Tyro3 tyrosine kinase activity, and use of these pyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.

  本发明包括选择性抑制Mer酪氨酸激酶（MerTK）活性和/或Tyro3酪氨酸激酶活性的嘧啶化合物，并将这些嘧啶化合物用作抗癌剂、免疫刺激剂和免疫调节剂、抗血小板剂、抗感染剂以及作为辅助剂与化疗、放疗或其他肿瘤标准治疗联合使用的药物。